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Introduction
Heart function fails when the organ is unable to pump 
blood at a rate proportional to the body’s need for oxygen 
or when this function leads to elevated cardiac chamber 
f illing pressures (cardiogenic pulmonary edema). Despite 
our sophisticated knowledge of heart failure, even the so-
called ejection fraction–preserved heart failure has high 
rates or mortality and morbidity. So, novel therapies are 
sorely needed. With over a million hospitalizations annu-
ally – up 175% over the past 25 years – and costs of nearly 
$15.4 billion dollars, acute heart failure is a critically 
important health concern. Furthermore, half of the patients 
discharged from the hospital are readmitted within half-a-
year. In-hospital mortality remains high between 4% and 
7%.1,2 Heart failure is a significant problem as the popula-
tion ages. The prevalence is 2.5% of the US population or 
5 million patients (from the National Health and Nutri-
tion Education Survey).2
Common etiological mechanisms of heart failure include 
coronary ischemia, valvular disease, hypertension, and 
diastolic dysfunction. Yet, other causes include: postpartum 
cardio myopathy; postinfectious, chronic tachycardia; metabolic 
dysregulation; adverse medication side effects (particularly adri-
amycin chemotherapy); orphan disease Duchenne’s muscular 
dystrophy; infiltrative diseases (such as amyloidosis); and inflam-
matory/connective tissue diseases (such as systemic lupus erythe-
matosus). When known causes of heart failure are excluded, then 
heart failure is classified as idiopathic. Less often studied versus 
chronic heart failure, acute decompensated heart failure is associ-
ated with abrupt-onset symptoms associated with hospitalization. 
Nearly half of the admitted patients with heart failure have pre-
served ejection fraction.2,3
In order to appreciate the physiology of heart failure, a review 
of fundamental principles is on order. The Frank– Starling Law 
states that the stroke volume of the heart increases in response 
to an increase in the volume of blood filling the heart (the end 
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diastolic volume) when all other factors remain constant. The 
increased volume of blood stretches the ventricular wall, causing 
cardiac muscle to contract more forcefully (the so-called Frank–
Starling mechanism). The stroke volume may also increase as a 
result of greater contractility of the cardiac muscle during exercise, 
independent of the end-diastolic volume. The Frank–Starling 
mechanism appears to make its greatest contribution to increas-
ing stroke volume at lower work rates, and contractility has its 
greatest influence at higher work rates.4
While the Frank–Starling mechanism may contribute at 
lower work rates, cardiac injury at lower work rates may activate 
additional mechanisms. Cardiac injury in heart failure leads to 
not only reduced left ventricular (LV) dysfunction but also acti-
vation of the renin angiotensin system and sympathetic nervous 
system, ultimately causing LV thickening, remodeling, vasocon-
striction (with pulmonary hypertension and cell dysregulation), 
and, possibly, apoptosis or programmed cell death. This sequence 
culminates in clinical heart failure – with attendant mortality 
and morbidity. Severity is graded by the New York Heart Asso-
ciation Class, with increasing severity of classes I to IV. Another 
grading system is the American Heart Association Staging 
System with stage C, classified as the symptomatic stage. This 
stage C is a result of known structural heart diseases and is asso-
ciated with shortness of breath, fatigue, and reduced exercise 
tolerance. The obvious goal is to prevent progressive LV dys-
function to end-stage D, resulting in LV assist device implanta-
tion, cardiac transplant, or palliative care.5
current standard Therapies
Medication management of acute heart failure often entails 
diuretics to reduce preload, vasodilators to reduce preload 
and/or afterload, and inotropes to augment contractility. 
Angiotensin-converting enzyme (ACE) inhibitors and angio-
tensin receptor blockers (ARBs) and aldosterone antagonists 
also aim to reduce preload and afterload.6 One adverse side 
effect (usually nonallergic antibody, non-IgE–mediated) of 
ACE inhibitors is angioedema (risk up to 15.5%). The risk 
of angioedema from ARBs is 4.4%. For ACE inhibitors, this 
angioedema results from increased bradykinin production, 
which can occur at any time while taking these medications 
due to interruption of the conversion of angiotensin I to 
angiotensin II. Angioedema from ACE inhibitors and ARBs 
may lead to life-threatening swelling of the throat, requir-
ing critical interventions, ie, intubation or tracheostomy. For 
ARBs, the mechanism of action of angioedema is not due to 
direct production of bradykinin and is unclear. Some chronic 
persistent angioedema may occur despite cessation of these 
medications. Some evidence suggests that treatment with 
a bradykinin B2 receptor blocker (icatibant) may attenuate 
angioedema attacks early.7–9 Patients with hereditary angioe-
dema (deficiency of C1 esterase inhibitor) and spontaneous 
attacks of swelling should not take ACE inhibitors. Clearly, it 
would be prudent to design a heart failure drug that does not 
incur risk of angioedema.
Other medications used for heart failure include inotropes – 
such as dopamine and dobutamine. While inotropes increase 
cardiac output, they often do so at the expense of increasing 
myocardial oxygen demand, predisposition to arrhythmias, and 
neurohormonal activation. Some patients may need invasive 
monitoring. Furthermore, inotropes do not improve mortality. 
There is 50% survival at 6 months and nearly 100% mortality 
at 1 year for those heart failure patients who are dependent 
on inotropes.10
Long-term survival among heart failure patients may be 
improved with β-blockers,11 ACE inhibitors,12 aldosterone 
antagonists,13 electrophysiology devices such as automatic 
implantable cardiovascular defibrillators, and vasodilators. 
Other drugs such as digoxin and diuretics do not alter death 
rates – digoxin reduces hospitalizations, while diuretics (furo-
semide or lasix) improve symptoms.
Another aspect of heart failure is diastolic dysfunction 
with preserved LV ejection fraction, accounting for half of 
the hospitalizations. Pathophysiologically, there is concentric 
remodeling and increased LV end diastolic pressure from a 
stiff left ventricle, thereby preventing relaxation. Medications 
for diastolic dysfunction are similar to systolic dysfunction: 
ACE inhibitors, ARBs, diuretics, and β-blockers.14
emerging Novel Therapies
LcZ696. In August of 2014, the first new drug for heart 
failure in many years, called LCZ696, was shown to prevent 
deaths and hospitalizations in heart failure patients – better 
than the gold standard enalipril, which is an ACE inhibitor. In 
the PARADIGN-HF study, LCZ696, which is comprised of 
two drugs – an ARB and a neprilysin inhibitor called sacubitril 
– reduced the risk of cardiovascular-related death to 13.3%, 
versus the ACE inhibitor cohort rate of 16.5%. This use of sacu-
bitril is an example of utilizing new or different pathways to 
treat heart failure.15
Sacubitril is a prodrug that is activated to LBQ657 by 
de-ethylation via esterases.16 LBQ657 inhibits the enzyme 
neprilysin,17 which is responsible for the degradation of atrial 
and brain natriuretic peptide, two blood pressure–lowering 
peptides that work mainly by reducing blood volume. As a 
result of reduced degradation of helpful peptides, these heart 
failure patients on sacubitril have less circulating blood vol-
ume and have done well in terms of prevention of deaths and 
hospitalizations (supra vide).
Ivabradine. On April 15, 2015, the Food and Drug Admini-
stration approved Corlanor (ivabradine) to reduce hospitaliza-
tions from worsening heart failure. The indications for ivabradine 
are specific: symptoms of heart failure that are stable and a nor-
mal heartbeat with a resting heart rate of at least 70 beats per 
minute and patients must already be taking β-blockers at the 
highest dose they can tolerate. Ivabradine is thought to work by 
decreasing heart rate and represents the first approved product in 
this drug class. It works via the If (funny channel) and does not 
affect other cardiac ionic currents (not beta receptor mediated). 
Novel therapies for heart failure
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Heart rate lowering with ivabradine reduces myocardial oxygen 
demand, simultaneously improving oxygen supply. There are no 
negative inotropic or lusitropic (myocardial relaxation) effects 
from ivabradine. Ventricular contractility is preserved.18 In clinical 
trials of 6,505 participants, hospitalizations for heart failure were 
reduced compared to placebo. The most notable side effects were 
bradycardia, hypertension, atrial fibrillation, and temporary visual 
disturbance entailing seeing flashes of light. The bradycardia may 
be severe.19
Vasoactive intestinal peptide. Other novel therapeutic 
agents for heart failure may consequently have plausible effi-
cacy on the heels of sacubitril and ivabradine. For example, 
Vasoactive intestinal peptide (VIP), discovered by Drs Sami I. 
Said and Victor Mutt in the 1970s, is a 28–amino acid pep-
tide found in nerve terminals and in mast cells.20 VIP increases 
cyclic adenosine monophosphate (cAMP) intracellularly to 
cause cardiac contraction in an analogous fashion to glucagon.21 
VIP also is a smooth muscle relaxant, which may be beneficial 
in pulmonary hypertension associated with heart failure22 and 
VIP inhibits the proliferation of smooth muscle cells, attenuat-
ing vascular remodeling.23
Inasmuch as sometimes vascular remodeling is a com-
pensatory mechanism for dysfunction in heart failure, VIP has 
promise to treat this deleterious component. Enhanced periph-
eral vascular tone is a major factor in determining deterioration 
of clinical heart failure. Nakamura has reviewed peripheral 
circulatory failure in heart failure and notes that it is caused 
“not only by simple arterial muscle constriction, but also by 
structural and functional changes, including receptor and post-
receptor levels in the vasculature.” Thus, vascular remodeling 
potentially may be an important mechanism underlying vaso-
dilatory failure in both limb conduit and intraskeletal muscle 
vessels, contributing significantly to LV dysfunction and exer-
cise intolerance in patients with heart failure.24
What is compelling about VIP as a novel therapeutic 
agent for heart failure is evident in mice lacking the gene for 
VIP. These mice have dilated cardiomyopathy. Human heart 
failure gene programs are overexpressed in VIP knockout 
mice.25 So, the plausibility of VIP as both a treatment for 
heart failure in patients and a modifier of one’s biology in a 
pharmacogenomic fashion may have traction.
Four categories of genes triggering heart failure are 
increased in mice without heart-protective VIP: (1) force gen-
eration and propagation; (2) energy production and regula-
tion; (3) Ca2+ cycling; and (4) transcriptional regulators. Force 
generation gene mutations encoding proteins of the muscle 
sarcomere have been associated with both hypertrophic and 
dilated cardiomyopathy. Overexpression of sarcomere protein 
expression in the setting of a dilated cardiomyopathy26 may 
suggest a compensatory mechanism. Upregulated expression of 
other force generation genes such as sarcoglycan and caveo-
lin27 in VIP knockout mice supports the concept of increased 
force to the extracellular matrix, with ventricular hypertro-
phy, for apparent release of protein products of these genes in 
heart failure.
Regarding energy production and regulation genes, it has 
been increasingly recognized that nuclear-encoded metabolic 
gene mutations are key regulators of hypertrophic cardiac 
remodeling and heart failure. For example, mutations in genes 
encoding the lysosome-associated membrane protein are asso-
ciated with heart failure in patients.28 In the absence of VIP 
in VIP knockout (KO) mice, upregulation of PRKAG2, for 
example,29 would support a compensatory response to thinning 
of the cardiac wall. Another category of gene program alteration 
Table 1. gene alterations related to hypertrophic/dilated cardiomyopathy in ViP Ko mice compared to wild-type (Wt) mice.
gENE SYmbol gENE NAmE Ko/wT (Fold CHANgE) P vAluE dESCRIpTIoN
casq1 calsequestrin 1 19 0.004 Calsequestrin is a major modulator of Ca2+ released from the 
sarcoplasmic reticulum. overexpression of these proteins 
induces cellular hypertrophy in cardiac myocytes.39,40casq2 calsequestrin 2 2 0.050
ttn titin (connectin) 10 0.004 loss of titin homeostasis in cardiomyocytes results in 
myocardial stiffness observed in patients with hypertensive 
heart failure and a preserved ejection fraction.41
cd59a cd59a 3.4 0.002 Cd59 proteins regulate assembly of the membrane attack 
complex. loss of function for both Cd59a and Cd59b variants 
result in a hemolytic phenotype.42 elevated levels of expres-
sion may result as a molecular response to prolong erythro-
cyte longevity and improve oxygen distribution in the setting of 
heart failure.
cd59b cd59b 1.5 0.007
lum lumican 3.3 0.010 “lumican is increased in experimental and clinical heart 
failure, and its production by cardiac fibroblasts is induced by 
mechanical and proinflammatory stimuli.”43
tPM1 alpha 
tropomyosine
2.9 0.008 Mutations that lead to dysregulation of this thin filament protein 
are associated with hypertrophic cardiomyopathies.44,45
des desmin 2.9 0.024 Upregulated in various forms of human heart failure.46
aCtC1 Cardiac actin 1.6 0.070 Mutations of cardiac thin filament proteins eg, ACTC1 result in 
hypertrophic cardiomyopathy, particularly lV hypertrophy.47,48
Note: heart failure–related genes are upregulated in ViP knockout mice.26
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– Ca2+ cycling – is critically important, since protein and RNA 
levels of key calcium modulators are altered in acquired and 
inherited forms of heart failure.
Overexpression of FKBP30 in mice supports the concept 
that these mice would have aberrant excessive release of cal-
cium during the relaxation/diastolic phase of the cardiac cycle, 
enhancing the opportunity to generate hypertrophy. Cardiac 
hypertrophy is attenuated in murine models with overexpression 
of Caveolin-3, a potent upstream inhibitor of T-type Ca2+ 
current,18 and rats treated with Calhex231, an inhibitor of 
calcium-sensing receptor.31 Similarly, deleterious LV hyper-
trophy may therefore plausibly be suppressed with exogenous 
Figure 2. right ventricular dilation is present in ViP knockout mice, with large areas of the rV shown in red approaching the size of the left ventricle.26 
these are end-diastolic multislice microMri images acquired in the coronal plane orientation (short-axis view). a control mouse heart is shown in the top 
panels and a ViP−/− mouse heart is shown in the bottom panels.
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Figure 1. ViP knockout mice have progressive right ventricular 
hypertrophy with age.25 Wild-type control is the left-most bar labeled Wt.
VIP administration. The fourth category of genetic alteration 
is transcriptional regulators. Mechanisms which activate or 
repress cardiac gene transcription may induce key molecules, 
which directly or indirectly lead to cardiac remodeling. Lack 
of VIP in VIP KO mice with the phenotype of biventricular 
dilated cardiomyopathy and primary pulmonary hypertension 
is concurrent with strong overexpression of cardiac muscle 
genes, supporting the concept of VIP in vivo as a maestro 
conductor maintaining homeostasis of the heart.26
Table 1 shows on the next page multiple heart failure 
gene programs which are overexpressed in VIP KO mice. 
An accompanying bar chart (Fig. 1) in blue demonstrates 
progressive right ventricular hypertrophy in these mice with 
age. MicroMRI (Fig. 2) additionally shows right ventricular 
dilation in VIP KO mice. These physiological abnormalities 
are associated with premature death compared to the wild 
type (Fig. 3). Compensatory and pathogenic gene programs 
are displayed in Figure 4, with overexpression of leptin as a 
compensatory reaction for cardiac cachexia and low body weight 
along with proinflammatory interleukin-6 (IL-6) and IL-1. 
VIP signal transduction is shown in Figure 6. VIP increases 
intracellular cAMP and acts via protein kinase A to activate 
transcriptional promoters.32,33 VIP upregulates IL-10, which 
is anti-inflammatory.34
Kupari et al found that VIP levels in serum from healthy 
subjects and patients with aortic stenosis and heart fail-
ure were released into the coronary sinus. VIP levels were 
higher in heart failure patients. These authors concluded 
that, although VIP was marginally elevated systemically in 
heart failure, it is the major neuroendocrine contributor to 
Novel therapies for heart failure
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Figure 3. severely increased mortality is seen in ViP Ko mice compared 
to wild-type.25 the cause of death was not determined. however, as 
shown in Figure 1, there is an association of progressive right ventricular 
hypertrophy with age.
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overexpression of leptin gene in ViP Ko mice may be a function of 
compensation for the “cardiac cachexia” leading to low body weight 
and lack of subcutaneous adipocytes. there is also overexpression of 
proinflammatory genes such as IL-6 and IL-1a.26
heart failure.35 Smitherman infused VIP into the left coro-
nary artery of four other men at four levels. The maximum 
decline in coronary vascular resistance was 46% and was not 
associated with an increase in myocardial oxygen uptake. 
He concluded that “1) intravenous administration of low to 
intermediate doses of VIP in humans is associated with sub-
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Figure 5. scatter gram of rV ed volumes measured in the short-axis 
magnetic resonance images of individual control mice (blue) and ViP Ko 
mice (red circles) demonstrating that the rV phenotype varied in the ViP 
Ko mice. right ventricular end diastolic volume is higher in some ViP Ko 
mice, suggesting diastolic dysfunction.26
stantial coronary vasodilation, 2) the coronary bed appears to 
be at least as responsive as other vascular beds, 3) the coronary 
vasodilation is due to both direct and indirect effects, and 
4) the coronary vasodilation does not appear to be mediated 
by prostaglandins.”36,37
So, the potential of an exogenous, sustainable VIP drug 
would be to help relax coronary arteries. Lucia et al also 
found that VIP plasma levels were higher in heart failure 
patients with dilated cardiomyopathy compared to healthy 
subjects and was higher in older subjects. Heart failure 
patients with higher New York Heart Association seve-
rity had lower levels of VIP. These data support a putative 
restorative role of VIP in treating disease. These data also 
suggest that heart failure patients with worse disease have 
an inability to produce VIP. The capacity of the elderly to 
produce VIP is heartening, so that low levels are not due to 
aging itself.38
PhaseBio Corporation recently conducted a phase 1, 
single ascending dose (SAD) study in patients with essential 
hypertension. PB1046 was administered subcutaneously and 
was found to be well-tolerated and demonstrated a prolonged, 
dose-dependent effect on blood pressure, which was used as a 
biomarker for activity in this study. (See http://clinicaltrials.
gov/ct2/show/NCT01523067 for further details.)
With this demonstration of safety and tolerability at 
efficacious doses, PhaseBio conducted a second phase 1 
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SAD study in patients with essential hypertension, with 
the product administered intravenously to support the use 
of PB1046 in an acute setting (http://clinicaltrials.gov/
show/NCT01873885). Subsequent phase 2 clinical stud-
ies will examine the efficacy of multiple ascending doses of 
PB1046 in patients with pulmonary arterial hypertension 
and heart failure.
conclusion
Current therapies do not control progression of heart fail-
ure well and must often be used in combinations to optimize 
results. Novel emerging therapies show promise with improved 
outcomes but many still have limitations. LCZ696 utilizes a 
novel pathway to treat heart failure and improves mortality in 
comparison to the current standard of care, enalipril. It is impor-
tant to remember that as a combination therapy utilizing an 
ARB, it carries a risk of inducing life-threatening angioedema. 
Ivabradine reduces rates of heart failure–related hospitalization, 
but the indications for use are strict and this medication carries 
undesirable side effects that potentiate etiologic mechanisms 
of heart failure. VIP, an endogenous peptide, shows widespread 
cardiovascular benefits as a vasodilator, an attenuator of smooth 
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Figure 6. ViP is recognized by three different g-protein–coupled receptors: pituitary adenylate cyclase-activating peptide receptor (PaC1), vasoactive 
intestinal peptide receptor 1 (VPaC1) and vasoactive intestinal peptide receptor 2 (VPaC2).49 these receptors share a common signal transduction 
pathway in which activation of adenylyl cyclase (aC) upregulates caMP production and subsequently activates protein kinase a (PKa).50–52 downstream 
effects of PKa activation regulate cardiovascular function.53–60
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muscle proliferation, and a homeostatic regulator of heart fail-
ure gene programs thereby preventing hypertrophy of cardiac 
myocytes. Endogenous levels of VIP have been shown to be ele-
vated in certain stages of heart failure. However, later stages of 
the disease show significantly diminished levels. Administration 
of exogenous VIP in early and late stages of heart failure may 
provide the most benefit for patients. Further research is war-
ranted. Use of an elastin polymer to protect and stabilize VIP 
as a therapeutic agent shows the interface between engineering 
and medicine, and it bodes well for the influence of technology 
on society, particularly since heart failure will continue to grow 
as a prevalent problem as the population ages. VIP may there-
fore have a chance to satisfy the unmet need as a treatment for 
acute heart failure, thus fulfilling discoverer Dr Sami I. Said’s 
dream to promote human health.
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